Systems Biology Ireland

ucd.ie

SBI established in 2009 under the Science Foundation Ireland CSET programme has successfully developed an integrated mathematical modelling and experimental research programme focusing on the design of new therapeutic approaches to cancer, degenerative and inflammatory diseases based on a systems level, mechanistic understanding of cellular signal transduction networks. SBI is one of the few centres in Europe with the necessary in house expertise, technologies and capabilities to apply systems biology approaches to mammalian models. It’s recognition internationally within the field of systems biology led to the Centre’s invited participation in three large European funded consortia initiatives in 2012 namely the ITFoM, CASyM and ISBE, the last of which is included on the ESFRI 2010 Roadmap.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industrial Impact

ENLAZA THERAPEUTICS LAUNCHES WITH $61 MILLION FINANCING TO ADVANCE THE FIRST COVALENT BIOLOGIC THERAPEUTIC PLATFORM

Enlaza Therapeutics | December 19, 2022

news image

Enlaza Therapeutics, the first covalent biologic platform company, announced its official launch with the closing of $61 million in seed financing. The financing was led by Avalon Ventures and joined by Lightspeed Venture Partners, Frazier Life Sciences, and Samsara BioCapital. The financing will be used to further advance Enlaza’s proprietary War-LockTM platform and build a pipeline of covalent biologics with an initial focus on developing novel, differentiated cancer therapeutics with ta...

Read More

Industrial Impact, Medical

PAIGE AND VISIOPHARM WORK TOGETHER TO DELIVER ADVANCED AI CANCER DIAGNOSTIC SUPPORT THROUGH THE PAIGE PLATFORM

Businesswire | May 05, 2023

news image

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications to assist in diagnosing cancer, announced it is working with Visiopharm, an artificial intelligence (AI)-driven precision pathology software provider, to bring a wider range of AI products to doctors and patients. Visiopharm’s AI applications will be deployed and natively integrated into the Paige Platform to be accessed through FullFolio™, Paige’s AI-powered clinical worklist, a...

Read More

AI

LABCORP AND PATHAI EXPAND THEIR PARTNERSHIP TO ACCELERATE USE OF AI-POWERED PATHOLOGY

PathAI, Labcorp | March 09, 2021

news image

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Deve...

Read More

Medical

INVEST ONTARIO SUPPORTS NEW BIOMANUFACTURING FACILITY IN HAMILTON

Invest Ontario | April 01, 2022

news image

Invest Ontario is supporting OmniaBio Inc. in launching a new biomanufacturing facility that will catalyze Ontario life sciences jobs and innovation while advancing pioneering medicine with the potential to cure, not just treat, many forms of cancer, cardiovascular diseases, Parkinson's and diabetes. OmniaBio, a Canadian cell and gene therapy contract development and manufacturing organization (CDMO), will be the anchor tenant in a new biomanufacturing campus being built in Ha...

Read More
news image

Cell and Gene Therapy, Industrial Impact

ENLAZA THERAPEUTICS LAUNCHES WITH $61 MILLION FINANCING TO ADVANCE THE FIRST COVALENT BIOLOGIC THERAPEUTIC PLATFORM

Enlaza Therapeutics | December 19, 2022

Enlaza Therapeutics, the first covalent biologic platform company, announced its official launch with the closing of $61 million in seed financing. The financing was led by Avalon Ventures and joined by Lightspeed Venture Partners, Frazier Life Sciences, and Samsara BioCapital. The financing will be used to further advance Enlaza’s proprietary War-LockTM platform and build a pipeline of covalent biologics with an initial focus on developing novel, differentiated cancer therapeutics with ta...

Read More
news image

Industrial Impact, Medical

PAIGE AND VISIOPHARM WORK TOGETHER TO DELIVER ADVANCED AI CANCER DIAGNOSTIC SUPPORT THROUGH THE PAIGE PLATFORM

Businesswire | May 05, 2023

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications to assist in diagnosing cancer, announced it is working with Visiopharm, an artificial intelligence (AI)-driven precision pathology software provider, to bring a wider range of AI products to doctors and patients. Visiopharm’s AI applications will be deployed and natively integrated into the Paige Platform to be accessed through FullFolio™, Paige’s AI-powered clinical worklist, a...

Read More
news image

AI

LABCORP AND PATHAI EXPAND THEIR PARTNERSHIP TO ACCELERATE USE OF AI-POWERED PATHOLOGY

PathAI, Labcorp | March 09, 2021

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Deve...

Read More
news image

Medical

INVEST ONTARIO SUPPORTS NEW BIOMANUFACTURING FACILITY IN HAMILTON

Invest Ontario | April 01, 2022

Invest Ontario is supporting OmniaBio Inc. in launching a new biomanufacturing facility that will catalyze Ontario life sciences jobs and innovation while advancing pioneering medicine with the potential to cure, not just treat, many forms of cancer, cardiovascular diseases, Parkinson's and diabetes. OmniaBio, a Canadian cell and gene therapy contract development and manufacturing organization (CDMO), will be the anchor tenant in a new biomanufacturing campus being built in Ha...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us